{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:19:58Z","timestamp":1769728798724,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004048","name":"Kashan University of Medical Sciences","doi-asserted-by":"publisher","award":["400119"],"award-info":[{"award-number":["400119"]}],"id":[{"id":"10.13039\/501100004048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["4000946"],"award-info":[{"award-number":["4000946"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunity Inflam &amp;amp; Disease"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vaccination plays a fundamental role in mastering the COVID\u201019 pandemic and protecting vulnerable groups. Persons with autoimmune inflammatory rheumatic diseases (AIIRD) requiring immunosuppressive therapies are prioritized for vaccination. However, data concerning immunogenicity and safety of the BBIBP\u2010CorV vaccine in immunosuppressed patients are not found. This study presents data on the efficacy and safety of the BBIBP\u2010CorV vaccine in immunosuppressed patients compared to healthy controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Study population consisted of 100 healthy controls and 100 patients with AIIRD. Vaccination was performed according to national guidelines with the BBIBP\u2010CorV vaccine. SARS\u2010CoV\u20102 neutralizing antibody titers were quantified by enzyme\u2010linked immunosorbent assay before initial vaccination and 1\u20133 months after secondary vaccination. Adverse events were assessed before study initiation and 7 days after the second dose. Disease activity was studied before entering the study and 3\u20138 weeks after the second dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Vaccination\u2010induced positive immunogenic response rates and SARS\u2010CoV\u20102 neutralizing antibody titers were significantly lower in the AIIRD patients than healthy subjects (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05). There are significant differences in neutralizing antibody titers among patients suffering from rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis, and ankylosing spondylitis (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.01\u2013.05). The rates of seropositive vaccine responses were similarly distributed across all diseases. Healthy and AIIRD individuals had a similar profile in adverse events. No significant difference was observed in SARS\u2010CoV\u20102 antibody titers between subjects suffering from side effects and those who did not have. SARS\u2010CoV\u20102 neutralizing antibody levels were significantly higher in subjects with a history of COVID\u201019 infection than seronegative individuals (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.01\u20130.05). Seropositive subjects had a significant increase in the percentage of vaccine\u2010related adverse events compared to seronegative persons (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.05). Despite a minor change in the disease activity of patients with RA and SLE, disease activity indices were overall stable in the AIIRD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings revealed that the BBIBP\u2010CorV vaccine is effective in the development of neutralizing antibodies in immunosuppressed patients without considerable reactogenicity or induction of disease flares.<\/jats:p><\/jats:sec>","DOI":"10.1002\/iid3.858","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T11:33:59Z","timestamp":1684236839000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunogenicity and safety of the BBIBP\u2010CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort"],"prefix":"10.1002","volume":"11","author":[{"given":"Batool","family":"Zamani","sequence":"first","affiliation":[{"name":"Autoimmune Diseases Research Center Kashan University of Medical Sciences Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Moradi Hasan\u2010Abad","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Center Kashan University of Medical Sciences Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Piroozmand","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Center Kashan University of Medical Sciences Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa","family":"Dehghani","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Center Kashan University of Medical Sciences Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Arfaatabar","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Sciences, Kashan Branch Islamic Azad University Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7372-4590","authenticated-orcid":false,"given":"Hossein","family":"Motedayyen","sequence":"additional","affiliation":[{"name":"Autoimmune Diseases Research Center Kashan University of Medical Sciences Kashan Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00073-5"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060901"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.34172\/ipp.2021.31"},{"issue":"1","key":"e_1_2_10_5_1","first-page":"1","article-title":"Effectiveness of the Pfizer\u2010BioNTech and Oxford\u2010AstraZeneca vaccines on covid\u201019 related symptoms, hospital admissions, and mortality in older adults in England: test negative case\u2010control study","volume":"373","author":"Bernal JL","year":"2021","journal-title":"BMJ"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.014"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10648-w"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220503"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04917-0"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220231"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-022-01089-6"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac089"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-05017-9"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102744"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01469-5"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27583"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3261-6"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2020.01.008"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.006"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/iji.12456"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209768"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13299"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220272"},{"issue":"1","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001898","article-title":"Immune responses to mRNA vaccines against SARS\u2010CoV\u20102 in patients with immune\u2010mediated inflammatory rheumatic diseases","volume":"8","author":"Santos CS","year":"2022","journal-title":"RMD Open"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2101667"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02055-9"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96129-6"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","unstructured":"Braun\u2010MoscoviciY KaplanM MarkovitsD et al.Humoral response to Pfizer mRNA vaccine against SARS CoV2 in patients with autoimmune inflammatory rheumatic diseases and the impact on the rheumatic disease activity.MedRxiv.2021(3):1\u20105.","DOI":"10.1101\/2021.04.02.21254493"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102743"}],"container-title":["Immunity, Inflammation and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/iid3.858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T18:21:59Z","timestamp":1744395719000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/iid3.858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/iid3.858"],"URL":"https:\/\/doi.org\/10.1002\/iid3.858","archive":["Portico"],"relation":{},"ISSN":["2050-4527","2050-4527"],"issn-type":[{"value":"2050-4527","type":"print"},{"value":"2050-4527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"2022-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e858"}}